![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KIAA1841 |
Gene summary for KIAA1841 |
![]() |
Gene information | Species | Human | Gene symbol | KIAA1841 | Gene ID | 84542 |
Gene name | SANT and BTB domain regulator of CSR | |
Gene Alias | KIAA1841 | |
Cytomap | 2p15 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q6NSI8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84542 | KIAA1841 | CCI_1 | Human | Cervix | CC | 2.54e-08 | 5.52e-01 | 0.528 |
84542 | KIAA1841 | CCI_2 | Human | Cervix | CC | 3.06e-08 | 5.60e-01 | 0.5249 |
84542 | KIAA1841 | CCI_3 | Human | Cervix | CC | 2.95e-09 | 5.33e-01 | 0.516 |
84542 | KIAA1841 | sample3 | Human | Cervix | CC | 1.19e-07 | 2.86e-01 | 0.1387 |
84542 | KIAA1841 | T3 | Human | Cervix | CC | 2.76e-06 | 2.85e-01 | 0.1389 |
84542 | KIAA1841 | HCC2_Meng | Human | Liver | HCC | 1.11e-02 | 6.36e-02 | 0.0107 |
84542 | KIAA1841 | HCC1 | Human | Liver | HCC | 3.09e-11 | 3.47e+00 | 0.5336 |
84542 | KIAA1841 | HCC2 | Human | Liver | HCC | 1.05e-13 | 2.89e+00 | 0.5341 |
84542 | KIAA1841 | S015 | Human | Liver | HCC | 1.44e-04 | 2.85e-01 | 0.2375 |
84542 | KIAA1841 | S028 | Human | Liver | HCC | 3.02e-05 | 2.71e-01 | 0.2503 |
84542 | KIAA1841 | S029 | Human | Liver | HCC | 2.08e-02 | 2.21e-01 | 0.2581 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KIAA1841 | SNV | Missense_Mutation | c.94N>G | p.Gln32Glu | p.Q32E | Q6NSI8 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
KIAA1841 | SNV | Missense_Mutation | novel | c.1823N>G | p.Lys608Arg | p.K608R | Q6NSI8 | protein_coding | tolerated(0.08) | benign(0.039) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
KIAA1841 | SNV | Missense_Mutation | rs376731071 | c.842N>T | p.Ser281Leu | p.S281L | Q6NSI8 | protein_coding | deleterious(0.01) | benign(0.047) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KIAA1841 | SNV | Missense_Mutation | c.883N>G | p.Phe295Val | p.F295V | Q6NSI8 | protein_coding | tolerated(0.09) | benign(0.094) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
KIAA1841 | SNV | Missense_Mutation | novel | c.1693N>C | p.Glu565Gln | p.E565Q | Q6NSI8 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
KIAA1841 | SNV | Missense_Mutation | rs756138624 | c.500N>T | p.Asp167Val | p.D167V | Q6NSI8 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KIAA1841 | SNV | Missense_Mutation | c.1027C>T | p.Pro343Ser | p.P343S | Q6NSI8 | protein_coding | tolerated(0.4) | benign(0.011) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
KIAA1841 | SNV | Missense_Mutation | novel | c.214T>C | p.Ser72Pro | p.S72P | Q6NSI8 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KIAA1841 | SNV | Missense_Mutation | novel | c.694N>A | p.Leu232Ile | p.L232I | Q6NSI8 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
KIAA1841 | SNV | Missense_Mutation | c.1339N>T | p.Arg447Trp | p.R447W | Q6NSI8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |